[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595124":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":39,"centralContacts":44,"locations":49,"responsibleParty":80,"collaborators":82,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":10,"enrollmentInfo":96,"targetDuration":10,"studyType":99,"phases":10,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Resuscitated OverCool clinical investigation participants alive at 28 days after cardiac arrest",null,"Patients who were resuscitated after cardiac arrest, treated with ultrarapid cooling as part of the OverCool clinical investigation and survived until the end of the investigation (28 days after cardiac arrest and subsequent Vent2Cool treatment).",[13,14,15,16,17],"Other: Short Form Health Survey (SF-36)","Other: Modified Rankin Score (mRS)","Other: Activity of Daily Living (ADL) questionnaire","Other: New York Heart Association (NYHA) Classification","Other: St George's Respiratory Questionnaire (SGRQ)",[19,23,27,31,35],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Short Form Health Survey (SF-36)","Heath-related quality-of-life is assessed using the SF-36 questionnaire, which is administered at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, in the form of a telephone interview.",[9],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Modified Rankin Score (mRS)","The degree of disability\u002Fdependence is evaluated using the mRS scale at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.",[9],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Activity of Daily Living (ADL) questionnaire","Level of independence is evaluated using the ADL questionnaire, which is administered at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, in the form of a telephone interview.",[9],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"New York Heart Association (NYHA) Classification","The extent of heart failure is assessed using the NYHA functional classification at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.",[9],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"St George's Respiratory Questionnaire (SGRQ)","Respiratory status is assessed using the SGRQ questionnaire at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.",[9],[40],{"name":41,"affiliation":42,"role":43},"Alain CARIOU, MD PhD","AP-HP, Cochin Hospital, Intensive Care and Resuscitation Department","PRINCIPAL_INVESTIGATOR",[45],{"name":41,"role":46,"phone":47,"phoneExt":10,"email":48},"CONTACT","+33 1 58 41 25 01","alain.cariou@aphp.fr",[50,68],{"facility":51,"status":52,"city":53,"state":10,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Angers University Hospital, Medical Intensive Care Unit, Vent'Lab","NOT_YET_RECRUITING","Angers","Alain MERCAT","France","FR",{"type":58,"coordinates":59},"Point",[60,61],-0.55202,47.47156,{"lat":61,"lon":60},[64],{"name":65,"role":46,"phone":66,"phoneExt":10,"email":67},"Alain MERCAT, MD PhD","+33 2 41 35 36 37","alain-mercat@univ-angers.fr",{"facility":69,"status":70,"city":71,"state":10,"zip":72,"country":55,"countryCode":56,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"AP-HP Centre, Cochin Hospital, Medical Intensive Care Unit","RECRUITING","Paris","75014",{"type":58,"coordinates":74},[75,76],2.3488,48.85341,{"lat":76,"lon":75},[79],{"name":41,"role":46,"phone":47,"phoneExt":10,"email":48},{"type":81,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[83],{"name":84,"class":85},"ORIXHA","INDUSTRY","100595124","long-term-follow-up-of-cardiac-arrest-survivors-exposed-to-ultra-rapid-cooling-100595124",false,"NCT07028372","Long Term Follow-up of Cardiac Arrest Survivors Exposed to Ultra-rapid Cooling","Long Term Follow-up of Cardiac Arrest Survivors Exposed to Ultra-rapid Cooling, a Prospective Non-interventional Cohort","AFTERCOOL","Inclusion Criteria:\n\n* Age of 18 years and over\n* Cardiac arrest patient included in and alive at the end of the OverCool clinical investigation (28 days after the cardiac arrest)\n* Non-opposition from the patient or the trusted person or the close relative or parent obtained within 3 months after the end of the OverCool study\n\nExclusion Criteria:\n\n* Follow-up refusal from patient of trusted person or the close relative or parent\n* Having being included in the OverCool clinical investigation but not submitted to the Vent2Cool procedure\n* Impossibility to reach the patient or the trusted person or the close relative or parent","ALL","18 Years",{"count":97,"type":98},12,"ESTIMATED","OBSERVATIONAL","Less than 10% of patients eliciting out-of-hospital cardiac arrest (OHCA) survive, although 30% can be resuscitated by Emergency services before admission in Intensive Care Units (ICU). The majority succumb to Post-Cardiac Arrest Syndrome (PCAS). PCAS is associated with high mortality (60-70%) and morbidity.\n\nOne proposed method of preventing the neurological and cardiac consequences of PCAS is to lower the body temperature to 33°C as quickly as possible. This approach is known as therapeutic hypothermia or Targeted Temperature Management (TTM). The Vent2Cool system, developed by Orixha, is a novel approach that enables the rapid induction of therapeutic hypothermia by using hypothermic Total Liquid Ventilation (TLV) to reach a protective temperature of 33°C within minutes.\n\nThe OverCool feasibility study, which started in April 2025, is designed to validate the clinical performance and safety of an ultra-rapid cooling approach combining ultra-rapid hypothermia induction using the Vent2Cool system, and maintenance and rewarming using the ArcticSun system.\n\nThe AfterCool study aims to evaluate long-term outcomes during a five-year follow-up of cardiac arrest survivors who were treated with ultrarapid cooling in the OverCool study.",[102,103,104],"Cardiac Arrest (CA)","Resuscitated Sudden Cardiac Death","Post Cardiac Arrest Patient Who Was Treated by Hypothermia Protocol",[106,107,108,109,110,111],"Cardiac arrest","Hypothermia","Target temperature management","Liquid ventilation","Resuscitation","long-term outcomes","2026-03-22",{"date":114,"type":115},"2026-03-24","ACTUAL",{"date":117,"type":115},"2025-06-11",{"date":119,"type":98},"2031-12",{"name":5,"class":6},2]